

# IMMUNOCORE

## Immunocore Highlights IMCgp100 clinical data in Uveal Melanoma at ASCO 2017 Annual Meeting

June 1, 2017

**(Oxford, UK and Conshohocken, US, 1 June 2017)** Immunocore Limited, the world's leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces that new clinical data from a second Phase I study of its lead programme, IMCgp100, will be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 3 June 2017.

The abstract will be presented by Dr Takami Sato, MD, PhD, Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, in the poster session Melanoma/Skin Cancers on Saturday 3 June, 13:15-16:45. The title of the abstract (number 9531, found at Poster Board number 139) is: **Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.**

**Chris Coughlin, Chief Medical Officer of Immunocore commented:** *"We continue to be excited by the compelling clinical data we are observing with IMCgp100 in patients uveal melanoma and are advancing our lead programme into a pivotal study. There are no treatments that have shown any survival benefit in this disease so the unmet need is high."*

Please click on the link below to download the full Press Release: